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Summary 
The receptors for the gonadotropins differ from the other G protein-coupled receptors by having a large 
extracellular hormone-binding domain, encoded by nine or ten exons. Alternative splicing of the large pre-mRNA of 
approximately 100 kb can result in mRNA species that encode truncated receptor proteins. In this review we discuss 
the regulation of gonadotropin receptor mRNA expression and the possible roles of alternative splicing in 
gonadotropin receptor function. 
Introduction 
In less than a decade, starting with the cloning of 
the &-adrenergic receptor (Dixon et al., 1986), it has 
becom.e apparent that all receptors that couple to the 
production of intracellular second messengers through 
GTP-binding proteins are members of a large gene 
family, with more than 100 members (Savarese and 
Fraser, 1992). The receptors of this superfamily are 
characterised by a hydrophobic domain that includes 
seven transmembrane segments. With the isolation of 
the cDNAs encoding the LH/CG, TSH and FSH 
receptors (McFarland et al., 1989; Parmentier et al., 
1989; Sprengel et al., 1990), a distinct subfamily of this 
superfamily manifested itself. The binding domain for 
the large dimeric hormone molecules is encoded by the 
first nine or ten exons of the respective genes, followed 
by a last exon that encodes the transmembrane and G 
protein-coupling domain. This domain consists of seven 
transmembrane segments connected by three extra- 
and th.ree intracellular loops and ends in a cytoplasmic 
tail. This gene structure allows for alternative splicing 
of the primary transcripts, which is not possible for the 
-- 
* Corresponding author. Tel.: + 31-10-4087340; Fax: +31-lo- 
4366832. 
Abbreviations: LH: luteinizing hormone, lutropin; FSH: follicle- 
stimulating hormone, follitropin; TSH: thyroid-stimulating hormone, 
thyrotropin; CG: chorionic gonadotropin. 
transcripts encoding the other G protein-coupled re- 
ceptors, because almost all other members of the re- 
ceptor superfamily are encoded by a single exon. 
We will focus on the regulation of the expression of 
the gonadotropin receptor genes, emphasizing the pos- 
sible role of alternative splicing of primary transcripts 
the expression and function of the receptors. 
The gonadotropin receptors 
The gonadotropins luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) are members of a 
distinct family of glycoprotein hormones, which also 
includes thyroid-stimulating hormone (TSH) and chori- 
onic gonadotropin (CG). Synthesized in the pituitary 
gland, or in the placenta in case of CG, these hor- 
mones consist of a common a-subunit and a hormone- 
specific p-subunit, both of which are glycosylated 
(Gharib et al., 1990). The p-subunit is the major deter- 
minant of the hormone specificity of receptor binding. 
Cloning of the gonadotropin receptors revealed that 
they are members of the G protein-coupled receptor 
family (Loosfelt et al., 1989; McFarland et al., 1989; 
Minegish et al., 1991; Sprengel et al., 1990). They share 
the transmembrane/ intracellular domain with the 
many other G protein-coupled receptors, but in addi- 
tion possess a large extracellular domain which is re- 
sponsible for most, if not all, aspects of hormone 
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binding and specificity of the receptor. In particular 
the presence of this extracellular domain places the 
LH/CG and FSH receptors in a distinct three-mem- 
bered subfamily, together with the TSH receptor which 
will not be discussed here. Most of the 100 or so G 
protein-coupled receptor genes now known consist of 
only a single exon containing all necessary coding in- 
formation: the open reading frame and the 5’- and 
3’untranslated regions. In the case of the go- 
nadotropin receptors, however, the receptor is encoded 
by ten or eleven exons separated by large introns, 
resulting in a large gene of about 100 kb. The extracel- 
lular binding domain is encoded by the first nine (FSH 
receptor) or ten (LH receptor) exons, but the trans- 
membrane domain still is encoded by a single exon, 
numbered 10 or 11 (Heckert et al., 1992; Koo et al., 
1991; Tsai-Morris et al., 1991). 
Regulation 
FSH and LH receptors are expressed mainly if not 
exclusively in the gonads. There is little information 
available about the DNA elements in the receptor 
genes that confer this marked tissue specificity, al- 
though consensus response elements for growth fac- 
tors, second messengers and steroid hormones are pre- 
sent in the S-flanking regions of the LH and FSH 
receptor genes (Heckert et al., 1992; Wang et al., 
1992). Within the gonads, the receptors are expressed 
in distinct cell types: in the testis, FSH receptors can 
only be found in Sertoli cells (Heckert and Griswold, 
1990, whereas LH receptors are expressed in the 
Leydig cells (Segaloff and Ascoli, 1993). In the ovary 
the situation is slightly more complex: FSH receptors 
are found in the granulosa cells, while LH receptors 
are present in both granulosa cells and theta cell layers 
(Camp et al., 1991). 
There is some information available about the ex- 
pression of LH and FSH receptors in the fetal and 
postnatal gonads. During testis development in imma- 
ture rats, LH receptor mRNA expression in the testis 
increases continuously, both as a fraction of total RNA 
and per total testis RNA until a constant level is 
reached in adult animals (Vihko et al., 1992). FSH 
receptor mRNA level per Sertoli cell decreases from 
birth until the rats are 21 days of age, when Sertoli 
cells have stopped dividing. Thereafter, total testicular 
FSH receptor mRNA expression does not change (our 
unpublished observations). However, in the adult testis 
several components of the FSH signaling pathway are 
clearly regulated: different levels of FSH receptor 
mRNA expression, FSH-binding, FSH-dependent 
CAMP production, and CRE-binding protein mRNA 
expression in Sertoli cells were found to be associated 
with different stages of the cycle of the spe~atogenic 
epithelium (Heckert and Griswold, 1991.; Kliesch et al., 
1992; Parvinen, 1993). 
In the ovary, some LH receptor mRNA species 
appear to be constantly expressed during fetal life, 
although mRNAs that encode functional receptor 
molecules are expressed starting from day 7 of postna- 
tal life only - see discussion of splice variants below 
(Sokka et al., 1992). 
Hormonal regulation of expression of gonadotropin 
receptors has been studied both in vivo and in vitro, in 
cell cultures. in the testis, there are differential effects 
of hormone administration on LH receptor mRNA 
levels in fetal/neonatal versus adult rats: hCG treat- 
ment of intact animals resulted in up-regulation of LH 
receptor mRNA expression in fetal/ neonatal testis, 
but in do~vn-regulation i  adult testis (Pakarinen et al., 
1990). In the mouse Leydig tumour cell line MA-lo, 
treatment of the cells with epidermal growth factor, 
phorbol ester (activation of protein kinase C> or with 
hCG or S-Br-CAMP resulted in rapid loss of LH recep- 
tor mRNA (Segaloff and Ascoli, 1993; Wang et al., 
1991b; Wang et al., 1991~). This loss was not a result of 
decreased stability of LH receptor mRNA induced by 
any of the compounds that were used, but rather was 
caused by a decrease in LH receptor gene transcription 
rate (Nelson and Ascoli, 1992). FSH receptor mRNA 
expression in Sertoli cells in vivo also is down-regu- 
lated rapidly by its homologous hormone, or by FSH, 
dibutyryl-CAMP or forskolin in cultured Sertoli cells 
(Themmen et al., 1991). However, in this case no 
decrease in the rate of FSH receptor gene transcrip- 
tion could be found, and it was inferred that FSH 
receptor mRNA stability is decreased by FSH action. 
In the ovary, studies of hormone effects on go- 
nadotropin receptor regulation are confounded by the 
fact that both LH and FSH receptors are expressed in 
the same cell type, the granulosa cells. In cultured 
granulosa cells isolated from estrogen-primed rats, both 
LH and FSH up-regulate their respective receptor 
mRNAs (Piquette et al., 1991; Tilly et al., 1992). When 
follicular growth is induced in immature female rats by 
treatment with pregnant mare serum gonadotropin, 
LH receptor mRNA expression in the growing follicles 
is increased, presumably through activation of FSH 
receptors. This action can be mimicked in vitro, by 
incubation of cultured granulosa cells with FSH 
(Piquette et al., 1991). Immediately after the ovulatory 
LH peak, either in intact cycling rats or when mim- 
icked by injection with hCG, both FSH and LH recep- 
tor mRNA levels are decreased significantly (Camp et 
al., 1991). With the appearance of corpora lutea LH 
receptor mRNA expression again increases (LaPolt et 
al., 1990). 
Thus, both in the testis and ovary, mechanisms exist 
that result in either up- or down-regulation of go- 
nadotropin receptor mRNA expression, depending on 
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cyclic changes or on the developmental stage of the 
gonads. It must be kept in mind that short-term changes 
in mRNA expression may not cause changes in recep- 
tor protein levels, independent of ligand-induced re- 
ceptor internalization. This is illustrated by the down- 
regulation of FSH receptor mRNA expression with 
dibutyryl-CAMP in cultured Sertoli cells, where disap- 
pearance of mRNA was not immediately followed by a 
decrease in hormone-binding (Themmen et al., 1991). 
Furthermore, the in vitro conditions under which cul- 
tured cells are treated with relatively high concentra- 
tions of hormone can result in an exaggerated and 
unchecked response. However, the responses of cells in 
vivo, such as for example the responses of Sertoli cells 
in developing testis or granulosa cells in growing folli- 
cles to FSH, probably occur under conditions of mod- 
erate stimulation (sub ED,,). They may be kept in 
check by paracrine mechanisms. 
Multiple mRNA species and splice variants 
Northern blot analysis of LH receptor mRNAs has 
resulted in the detection of several mRNAs with dis- 
tinct sizes. LH receptor cDNA probes revealed at least 
four LH receptor mRNA species: 6.5, 4.3, 2.6 and 1.2 
kb (Wang et al., 1991a). Similar sizes were reported by 
other investigators (Camp et al., 1991; Piquette et al., 
1991). These mRNA species can be differentially regu- 
lated. In the developing rat testis, the smaller tran- 
scripts were apparent at five days after birth, whereas 
all mRNA species were present from day 25 onwards 
(Vihko et al., 1992). Treatment of pseudopregnant rats 
with hCG resulted in down-regulation of all detectable 
LH receptor mRNA species. However, in the testis of 
hCG-treated rats, the 1.2 kb mRNA persisted, while 
Fig. 1. LH receptor (A) and FSH receptor (B) gene splice variants. 
Stippled box: original open reading frame; black box: translated 
intron or exon sequences with a different reading frame; black line: 
untranslated exon or intron sequences. (A) 1: full-length LH recep- 
tor; 2: porcine LHR-B (Loosfelt et al., 1989), rat LHR-1234 (Aatsinki 
et al., P992), rat LHR-B (Bernard et al., 19901, rat LHR-B4 (Segaloff 
et al., 1990; Tsai-Morris et al., 1990); 3: porcine LHR-C (Loosfelt et 
al., 1989); 4: porcine LHR-D (Loosfelt et al., 1989); 5: rat LHR-E 
(Bernard et al., 19901, rat LHR-A2 (Segaloff et al., 1990); 6: rat 
LHR-EB (Bernard et al., 1990); 7: rat LHR-Bl (Segaloff et al., 
1990); 8: rat LHR-B2 (Segaloff et al., 19901, rat LHR-2075 (Aatsinki 
et al., 1992); 9: rat LHR-B3 (Segaloff et al., 1990); 10: rat LHR-Cl 
(Segaloff et al., 1990); 11: rat LHR-C2 (Segaloff et al., 1990); 12: rat 
LHR-1950 (Aatsinki et al., 1992); 13: rat LHR-1759 (Aatsinki et al., 
1992). (B) 1: full-length FSH receptor; 2: human FSHR-E (Gromoll 
et al., 1992); 3: human FSHR-5-10 (Kelton et al., 1992); 4: rat 
FSHR-1 (Kraaij et al., unpublished observations); 5: rat FSHR-2 
(Kraaij et al., unpublished observations); 6: ovine FSHR-HK18 (Khan 
et al., 1993); 7: ovine FSHR-151Al (Khan et al., 1993). 6 and 7 are 
the result of both alternative splicing and alternative polyadenyla- 
tion. 
the other mRNAs were down-regulated (LaPoh et al., 
1991). Reprobing the same Northern blot with a trans- 
membrane/ intracellular domain-specific probe re- 
vealed that this 1.2 kb mRNA did not contain a portion 
of the transmembrane/ intracellular domain (LaPolt et 
al., 1991). Possibly, the 1.2 kb LH receptor mRNA 
encodes a truncated receptor protein (see below). 
The existence of aberrant mRNA species should not 
be surprising. Aberrant expression could result from 
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mistakes made by the splicing machinery during the 
conversion of the long primary transcript (100 kb) to 
the mature mRNA. Indeed, when the LH receptor 
cDNA was first reported, investigators howed cDNA 
variants that are probably the result of alternative 
splicing (McFarland et al., 1989). The list of LH recep- 
tor mRNA splice variants is growing (see Fig. 1A). 
Some of the variants have been found when cDNA 
libraries were screened for the full-length receptor 
cDNAs, while other research groups have used reverse 
transcriptase-polymerase chain reaction strategies in a 
more targeted effort to find other divergent LH recep- 
tor mRNAs (Aatsinki et al., 1992). 
Many of the gonadotropin receptor splice variants 
encode at least a partially intact hormone-binding do- 
main. Indeed, translation of a cloned cDNA resulted in 
a truncated protein without a transmembrane/ 
intracellular domain, but which was able to bind hCG 
(Tsai-Morris et al., 1990). Similar observations have 
been reported for pig LH receptor cDNAs (VuHai-Lu- 
uThi et al., 1992). The latter authors reported secretion 
of a portion of the truncated LH receptor molecules, 
but other investigators tudying similarly truncated CD- 
NAs have not confirmed this observation (Ji and Ji, 
1991; Xie et al., 1990). Actually, there are no indica- 
tions that mRNAs encoding truncated, but hormone- 
binding, receptors are expressed at significant levels. If 
they are, these mRNAs may not be translated under 
physiological conditions. In the ovary, Sokka et al. 
(1992) have shown the existence of alternatively spliced 
LH receptor transcripts missing the transmembrane/ 
intracellular domain encoding exon. They propose that 
the expression of these transcripts represents a default 
pathway which may have a physiological role in the 
developmental regulation of LH receptor expression in 
the ovary. This hypothesis implies that the LH receptor 
gene is constantly turned on, but complete mRNAs 
encoding intact LH receptor molecules are generated 
not until after day 7 of neonatal life, in the rat. How- 
ever, the expression of the splice variants is very low at 
all stages of development (Sokka et al., 1992). Further 
information on the expression and translation of trun- 
cated LH receptor mRNAs is eagerly awaited, to try to 
clarify the possible role of truncated receptor proteins 
in the regulation of physiological responses to LH. 
With regard to mRNA splice variants of the FSH 
receptor, similar results have been obtained (Fig. 1B). 
Several splice variants have been identified (Gromoll 
et al., 1992; Kelton et al., 1992; Khan et al., 1993). We 
also have cloned two FSH receptor mRNA splice vari- 
ants from rat Sertoli cells (Fig. lB), and studied their 
expression in testis and ovary using transcript-specific 
RNase protection probes. At different developmental 
stages (testis) and stages of the cycle (ovary), expres- 
sion of the splice variants closely followed expression 
of the full-length FSH receptor mRNA, as indicated by 
a constant ratio of splice variant over intact mRNA 
levels (Kraaij et al., unpublished observations). 
Receptor mRNAs encoding truncated receptor 
forms without a transmembrane/ intracellular domain 
are not limited to the gonadotropin receptors. They 
have also been found for the TSH, IL-4 and IL-7 
receptor genes (Goodwin et al., 1990; Mosley et al., 
1989; Pleiman et al., 1991; Takeshita et al., 1992). Yet, 
the possible function of expressed splice variants re- 
mains an enigma. If secreted, soluble receptor ligand- 
binding domains might act as inhibitors of hormone 
action by sequestering the ligand away from the full- 
length receptor. In this respect it is of interest that 
soluble IL-4 receptors, when transfected into cell lines, 
are secreted and inhibit the IL-4 effects that require 
the full-length receptor (Mosley et al., 1989). For the 
growth hormone receptor gene, a circulating growth 
hormone-binding protein has been identified in mouse 
and rat, that is encoded by an alternatively spliced 
receptor mRNA (Baumbach et al., 1989; Smith and 
Talamantes, 1987). In contrast to such inhibitory ef- 
fects, a free ligand-binding domain of truncated recep- 
tors might act to present the hormone to the receptor 
resulting in a more efficient signal. Other mechanisms, 
such as an intracellular role of non-secreted truncated 
receptor, cannot be excluded. 
Recently, two studies were reported which point to 
interaction between full-length LH receptors and trun- 
cated forms. Remy et al. (1993) showed that co-expres- 
sion of the extracellular binding domain and the trans- 
membrane/ intracellular domain resulted in reconsti- 
tution of a high-affinity LH receptor, which was able to 
bind hCG and to transduce the hormonal signal to 
adenylyl cyclase. Although the mechanism is unclear, 
this observation would seem to suggest hat domains of 
the receptor can function and cooperate as separate 
entities. Another intriguing observation was made in a 
study using co-expression of full-length and truncated 
LH receptor cDNAs (VuHai-LuuThi et al., 1992). Ex- 
pression of cDNA lacking the transmembrane/ 
intracellular domain in transfected COS cells resulted 
in high-affinity binding, but no stimulation of CAMP 
production. However, co-expression of both full-length 
and truncated receptors resulted in enhanced stimula- 
tion of adenylyl cyclase by hCG. This enhancement was 
the result of an increase in the maximal hormone-in- 
duced CAMP level, and not from a decrease in the 
ED,, for hCG, invalidating a model in which hormone 
is presented to the intact receptor by a soluble trun- 
cated form. 
The cloning of the gonadotropin receptors has pro- 
vided the tools to study the molecular regulation of 
receptor expression. The finding of splice variants has 
left us with many intriguing questions, but also may 
open up new frontiers concerning the regulation of 
hormonal transmembrane signaling. 
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